COTY vs IPAR: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
COTY and IPAR are similarly sized, but COTY trades noticeably cheaper on forward earnings (15.51x vs 26.75x): the market is paying up for IPAR's profile and pricing COTY more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
COTY vs IPAR: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | COTY | IPAR | What it tells you |
|---|---|---|---|
| Market cap | $3.77B | $4.36B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 15.51 | 26.75 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.85 | 1.09 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 97% of range | 97% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.21 | 4.96 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: COTY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how COTY and IPAR affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COTY and IPAR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COTY and IPAR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Coty Inc (COTY) do?
Coty Inc is one of the world's largest beauty companies, operating through two reporting segments. Prestige, which makes up roughly 60% of sales, is anchored by licensed luxury fragrances (Burberry, Hugo Boss, Calvin Klein, Davidoff, Marc Jacobs, Chloe, and Gucci for now) plus owned or licensed makeup lines such as Kylie Cosmetics. Consumer Beauty covers mass-market cosmetics and skincare, including CoverGirl, Max Factor, Rimmel, Sally Hansen and Bourjois. The company was assembled largely through acquisitions, notably the 2016 purchase of Procter & Gamble beauty brands, which left it carrying a heavy debt load. Investment firm JAB remains the controlling shareholder with a majority stake, and Coty added a dual listing on the Paris Stock Exchange to broaden its investor base.
What does Inter Parfums, Inc. (IPAR) do?
Interparfums creates, manufactures and distributes prestige fragrances under licence from brand owners. It signs a multi-year agreement with a fashion or jewellery house, pays that house a royalty of roughly 6% to 11% of net sales, and takes on everything else: the juice, the bottle, the positioning, the advertising and the distribution into more than 120 countries. The business runs in two segments. European based operations sit inside Interparfums SA, a separately listed Paris subsidiary that Interparfums owns 72% of, and carry Jimmy Choo, Coach, Montblanc, Lacoste, Boucheron, Kate Spade, Karl Lagerfeld, Moncler and Van Cleef & Arpels; that side was about 68% of 2025 net sales. United States based operations carry GUESS, Donna Karan/DKNY, Ferragamo, Abercrombie & Fitch, Hollister, MCM, Roberto Cavalli, Graff, Oscar de la Renta and Anna Sui. A handful of brands are owned outright rather than licensed, including Rochas, Lanvin, Off-White, Goutal and the in-house Solférino line.
COTY vs IPAR: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- COTY drivers: Prestige fragrance as the growth engine; Balance sheet repair and deleveraging.
- IPAR drivers: The licence book runs long where the revenue is; A staggered pipeline of new names.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The biggest risk is execution: Coty is mid-turnaround with declining like-for-like revenue, a fiscal 2026 net loss of about $618 million, and a Consumer Beauty business that took a large non-cash impairment. For IPAR, the structural risk is that Interparfums does not own most of what it sells, and a licensor can decline to renew or take fragrance in-house, as Alfred Dunhill did when that agreement lapsed on September 30, 2023 without renewal.
COTY or IPAR: which should you pick?
COTY vs IPAR: the full fundamentals
COTY. At about 0.5 times sales and roughly 13 times forward earnings, Coty is priced as a distressed turnaround rather than a steady beauty compounder, and the average analyst target of about $2.66 sits below the current price with a consensus hold rating. For the September quarter, due around November 5, 2026, analysts expect adjusted EPS of about $0.12 on roughly $1.53 billion of revenue, in line with management's 11-13 cent guide. Reported numbers have been distorted by one-time items such as the Wella disposal loss and the Consumer Beauty impairment, so always verify the latest quarterly release, balance sheet and any updated guidance from primary sources before making a decision.
IPAR. The multiple sits close to the broad market even though the earnings line is guided down this year, and the stock is up about 35% in 2026, which suggests the market is pricing the 2027 and 2028 launch slate (now including PUMA) rather than the current run rate. Analysts' average target of about $126.50 sits roughly 9% above the October 16, 2026 close. Three brokers cut the stock to a hold rating in August 2026 on exactly that reasoning, arguing the pipeline was already in the price. Royalty expense of ~$121.7 million in 2025, about 8.2% of sales, is the recurring cost of the licensing model and rises with brand mix rather than with volume alone.
Headline figures (approximate, October 2026): COTY shows revenue (ttm) ~$5.8 billion (fiscal 2026, ended June 30), down ~1% from ~$5.9 billion, latest quarter (fiscal q4 2026) ~$1.27 billion revenue, +1% reported, -1% like-for-like; adjusted EPS -$0.02 vs ~-$0.01 expected, margins Gross ~63%; operating ~-2%; net ~-10% (TTM), net income (ttm) ~-$618 million (loss, including impairments); IPAR shows revenue (ttm) ~$1.50B, up ~2% year over year in the latest quarter, diluted eps (ttm) ~$5.24, against 2026 guidance of ~$4.85; Q2 2026 EPS $0.95 vs $0.97 expected, net income (ttm) ~$168M, operating margin (h1 2026) ~17.9%, down from ~20.0% a year earlier; gross margin ~58% TTM.
The bottom line: COTY vs IPAR
COTY and IPAR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined COTY and IPAR exposure against your real portfolio. It is not an investment adviser.
Wondering how COTY or IPAR fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Coty Inc
Ask Walnut's AI anything about COTY and see how it fits what you own.
FAQ
What is the difference between COTY and IPAR?
+
Coty Inc is one of the world's largest beauty companies, operating through two reporting segments. Interparfums creates, manufactures and distributes prestige fragrances under licence from brand owners. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is COTY or IPAR the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, COTY or IPAR?
+
On forward P/E (as of November 2026), COTY trades at 15.51x and IPAR at 26.75x, so COTY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both COTY and IPAR?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of COTY vs IPAR?
+
COTY: The biggest risk is execution: Coty is mid-turnaround with declining like-for-like revenue, a fiscal 2026 net loss of about $618 million, and a Consumer Beauty business that took a large non-cash impairment. The company gave no full-year fiscal 2027 outlook and guided its first quarter to lower like-for-like sales, lower gross margin and lower EBITDA, while an interim (rather than permanent) CEO adds uncertainty about strategic direction. Losing the Gucci license after June 2027 shrinks the prestige portfolio. Even after the Wella sale, the company still carries about $3.1 billion of debt, so profitability pressure from promotions, tariffs and a shift toward lower-margin regions matters. The strategic review of mass brands may not produce attractive sale prices or timing. JAB's controlling majority stake means minority shareholders have limited influence, and beauty demand is cyclical and competitive. Currency swings also move reported results given global exposure, and a share price near $3 can swing sharply: it ranged from about $1.82 to $4.34 over the past year. IPAR: The structural risk is that Interparfums does not own most of what it sells, and a licensor can decline to renew or take fragrance in-house, as Alfred Dunhill did when that agreement lapsed on September 30, 2023 without renewal. Three smaller licences reach their stated end on December 31, 2026 (Anna Sui, Graff and Moncler), each with an optional extension that depends on conditions or sales targets being met, while Boucheron's main lines run to the end of 2027 and Abercrombie & Fitch and Hollister expire on March 14, 2028. Concentration compounds the point, because roughly 77% of sales sit in seven brands and Macy's alone was about 10% of 2025 net sales. Currency is a live swing factor given that about half of European segment sales are billed in dollars while nearly all of that segment's costs are in euro. There is also an option on the Lanvin trademarks that lets the seller repurchase them on July 1, 2027 for 70 million euro, roughly $82 million, which would remove an owned brand from the portfolio, and the 2026 guidance itself implies lower earnings than 2025 as advertising spend climbs back toward the company's 21% of sales target. Valuation is another consideration after the 2026 rally: at roughly 22 times trailing earnings and a similar multiple on 2027 estimates of about $5.20, the shares already price in much of the launch slate, and six analysts tracked carry a consensus hold rating.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell COTY or IPAR; figures are approximate and dated (as of November 2026). Verify current data before investing.